COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus (COMBAT)

AstraZeneca

Status: Completed

Conditions: Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT00526279

NIS-CKR-ATA-2007/2

Details and patient eligibility

About

To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.

Enrollment: 9,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients who have consented to participation/data release in this study
2. Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision

Exclusion criteria

1. Secondary hypertension requiring therapy other than antihypertensive medication
2. Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
3. Women in pregnancy or lactation
4. Patients enrolled in any other studies